{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:28:22Z","timestamp":1767148102979,"version":"build-2238731810"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jval.2021.11.1364","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T09:22:05Z","timestamp":1641892925000},"page":"965-974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting"],"prefix":"10.1016","volume":"25","author":[{"given":"Adrian","family":"Peacock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Dehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar Alejandro","family":"Mesa Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colman","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2021.11.1364_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ajd.12349","article-title":"Mycosis fungoides and S\u00e9zary syndrome: current challenges in assessment, management and prognostic markers","volume":"57","author":"Hughes","year":"2016","journal-title":"Australas J Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.11.1364_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1364_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement updates from the UK Photopheresis Society","volume":"177","author":"Alfred","year":"2017","journal-title":"Br J Haematol"},{"issue":"suppl 4","key":"10.1016\/j.jval.2021.11.1364_bib4","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann oncol"},{"key":"10.1016\/j.jval.2021.11.1364_bib5","unstructured":"Primary cutaneous lymphomas. clinical practice guidelines in oncology. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed June 2, 2020."},{"issue":"16","key":"10.1016\/j.jval.2021.11.1364_bib6","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with S\u00e9zary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1364_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/09546634.2017.1412064","article-title":"An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma","volume":"29","author":"Geskin","year":"2018","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1364_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2133.2005.06857.x","article-title":"Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group","volume":"154","author":"McKenna","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1364_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2133.2007.08415.x","article-title":"U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease","volume":"158","author":"Scarisbrick","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1364_bib11","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/ajd.13467","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Australian clinical practice statement","volume":"62","author":"Bhabha","year":"2021","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1364_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.jval.2021.11.1364_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.jval.2021.11.1364_bib15","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.jval.2021.11.1364_bib18","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of Brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10094","key":"10.1016\/j.jval.2021.11.1364_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jval.2021.11.1364_bib21","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/jdv.14366","article-title":"Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma","volume":"31","author":"Schiller","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1364_bib22","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2001.19.3.812","article-title":"Patient preferences for adjuvant interferon alfa-2b treatment","volume":"19","author":"Kilbridge","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1364_bib23","first-page":"16","article-title":"Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin\u2019s lymphoma: a United States payer perspective","volume":"22","author":"Large","year":"2019","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1364_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clinthera.2016.12.012","article-title":"Cost-effectiveness analysis\u00a0for apixaban in the acute treatment and prevention of venous thromboembolism in The Netherlands","volume":"39","author":"de Jong","year":"2017","journal-title":"Clin Ther"},{"issue":"21","key":"10.1016\/j.jval.2021.11.1364_bib25","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.jval.2021.11.1364_bib26","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","article-title":"Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Swinburn","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1364_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archderm.1995.01690170063009","article-title":"Assessing the preferences of patients with psoriasis. A quantitative, utility approach","volume":"131","author":"Zug","year":"1995","journal-title":"Arch Dermatol"},{"issue":"25","key":"10.1016\/j.jval.2021.11.1364_bib28","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jval.2021.11.1364_bib29","first-page":"681","article-title":"Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma","volume":"154","author":"Trager","year":"2019","journal-title":"G\u00a0ital dermatol venereol"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1364_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2008.05.038","article-title":"Extracorporeal photopheresis for the treatment of S\u00e9zary syndrome using a novel treatment protocol","volume":"59","author":"Arulogun","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jval.2021.11.1364_bib31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1364_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) [published correction appears in Blood. 2007;109(12):5086]","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jval.2021.11.1364_bib33","author":"Woolacott"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.11.1364_bib34","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.jval.2020.04.578","article-title":"PMD8 Cost-effectiveness of extracorporeal photopheresis for the treatment of erythrodermic (stage T4, M0) cutaneous T-cell lymphoma patients in the Australian setting","volume":"23","author":"Dehle","year":"2020","journal-title":"Value Health"},{"issue":"18","key":"10.1016\/j.jval.2021.11.1364_bib35","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jval.2022.09.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521031958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521031958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T03:11:50Z","timestamp":1688440310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521031958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1098301521031958"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.11.1364","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T4, M0) Cutaneous T-Cell Lymphoma in the Australian Setting","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.11.1364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}